Overview

The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction

Status:
NOT_YET_RECRUITING

Trial end date:
2027-01-01

Target enrollment:

Participant gender:

Summary

This study is a prospective interventional cohort study aimed at evaluating the therapeutic efficacy and clinical utility of Mavacamten-a targeted myosin inhibitor specifically developed for obstructive hypertrophic cardiomyopathy (HCM)-in patients with HCM characterized by mid-to-apical left ventricular obstruction.

Phase:

PHASE4

Details

Lead Sponsor:

Second Affiliated Hospital, School of Medicine, Zhejiang University

Treatments:

Adrenergic beta-Antagonists
Bisoprolol
Carvedilol
Diltiazem
Metoprolol
MYK-461